Journal of Asian Natural Products Research
483
J ¼ 14.4 and 4.4 Hz, H-30a), 2.76 (1H, dd,
J ¼ 14.4 and 3.6 Hz, H-30b); 13C NMR
(100 MHz, MeOH-d4): d 169.4 (s, C-10),
168.7 (s, C-1), 157.7 (s, C-400), 131.3 (d, C-
200), 131.3 (d, C-600), 129.9 (s, C-100), 116.3
(d, C-300), 116.3 (d, C-500), 56.5 (d, C-20),
45.7 (d, C-2), 37.6 (t, C-700), 37.0 (t, C-30);
(þ)-ESI-MS: m/z 267 [M þ H]þ and 289
[M þ Na]þ; (þ)-HR-ESI-MS: m/z
289.06232 [M þ Na]þ (calcd for C12H14
NaN2O3S, 289.06228).
1244, 1176, 1129, 1048, 1025, 1000, 827,
765 cm21; 1H NMR (500 MHz, DMSO-d6)
and 13C NMR (125 MHz, DMSO-d6
þ D2O) data: see Table 1; positive-mode
ESI-MS: m/z 243 [M þ Na]þ; (2)-ESI-
MS: m/z 219 [M 2 H]2; (2)-HR-ESI-MS:
m/z 219.0687 [M 2 H]2 (calcd for
C12H11O4, 219.0657).
3.3.5 Acid hydrolysis of 1 and 2, and
Marfey’s analyses of the hydrolyzates
Compound 1 (1.6 mg) or compound 2
(0.9 mg) was dissolved in 6 mol/l HCl
(0.5 ml), and heated at 1108C in a sealed
vial for 13 h. The cooled reaction
mixture was evaporated to dryness under
reduced pressure, and HCl was removed
from the residue of the acid hydrolyzate by
repeated evaporation from frozen water
(1.5 ml). The amino acid mixture was
dissolved in water (40 ml), and then treated
with 1% FDAA in acetone (100 ml) and
6% triethylamine (Et3N) in 50 ml of water
at 408C for 1 h. After cooling to room
temperature, the derivative and the stan-
dard amino acid samples were derivatized
in the same manner as the acid hydrolyzate
above (1% FDAA and 6% Et3N), were
filtered, and the filtrates were analyzed
by HPLC (Alltima RP-C18, 5 mm,
250 £ 4.6 mm, flow rate: 1 ml/min,
UV detection at 340 nm, mobile phase:
3.3.2 Cyclo(L-Val-D-Tyr) (2)
20
A white amorphous powder; ½aꢀD þ39.4
1
(c ¼ 0.22, MeOH); H NMR (500 MHz,
DMSO-d6): d 9.22 (1H, s, HO-40), 8.01
(1H, s, NH), 7.84 (1H, s, NH), 6.94 (2H, d,
J ¼ 8.5 Hz, H-20 and H-60), 6.61 (2H, d,
J ¼ 8.5 Hz, H-30 and H-50), 4.10 (1H, m,
H-80), 3.54 (1H, m, H-2), 3.03 (1H,
dd, J ¼ 14.0, 4.0 Hz, H-70a), 2.72
(1H, dd, J ¼ 14.0, 4.5 Hz, H-70b), 1.40
(1H, m, H-3), 0.59 (6H, d, J ¼ 7.0 Hz,
H3-4 and H3-5); (þ)-ESI-MS: m/z 263
[M þ H]þ.
3.3.3 2-Hydroxy-2-(40-hydroxybenzyl)-
4-methylcyclopent-4-ene-1,3-dione (3)
20
A yellowish gum; ½aꢀD < 0 (c ¼ 0.12,
CHCl3); UV (MeOH) lmax (log 1): 227
(4.37), 270 (0.75) nm; IR nmax: 3392,
2920, 1750, 1700, 1670, 1612, 1515, 1441,
1377, 1313, 1236, 1174, 1114, 1070,
35%
CH3CN/H2O þ 1%
HOAc).
The FDAA derivatives of amino
acids liberated from 1 showed a peak at
9.21 min, matching the retention time of
FDAA L-cysteine (9.17 min; 12.14 min for
D –); those liberated from 2 showed peaks at
14.81 and 12.79 min, matching the retention
times of FDAA L-valine (14.86 and
26.83 min for D –) and D-tyrosine (12.85
and 10.24 min for L –).
1028, 930, 896, 836, 790, 754 cm21; H
1
NMR (500 MHz, CDCl3) and 13C NMR
(125 MHz, CDCl3) data: see Table 1; (þ)-
ESI-MS: m/z 255 [MþNa]þ; (þ)-HR-
ESI-MS: m/z 255.0679 [MþNa]þ (calcd
for C13H12NaO4, 255.0633).
3.3.4 2-Hydroxy-4-hydroxymethyl-3-
(40-hydroxyphenyl)cyclopent-2-enone (4)
20
Acknowledgements
A yellowish amorphous powder; ½aꢀD < 0
Financial support from the National Natural
Sciences Foundation of China (NNSFC;
Grant Nos 30825044 and 20932007),
and the Program for Changjiang Scholars
(c ¼ 0.17, MeOH); UV (MeOH) lmax
(log1): 227 (0.66), 325 (1.52) nm; IR nmax:
3365, 1677, 1605, 1515, 1444, 1386, 1275,